Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL T LIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1164436820
CMS profile
98087
Location
SHERMAN OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,634.19

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,634.19 92

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $355.19 22
Amgen Inc. $241.61 8
UCB, Inc. $227.01 11
SUN PHARMACEUTICAL INDUSTRIES INC. $142.03 7
PFIZER INC. $131.11 14
Novartis Pharmaceuticals Corporation $129.93 9
Biofrontera Inc. $94.01 4
Incyte Corporation $68.85 3
Lilly USA, LLC $65.77 3
Allergan, Inc. $64.81 4
Galderma Laboratories, L.P. $26.90 2
Phadia US Inc. $21.74 1
LEO Pharma Inc. $18.86 1
BOSTON SCIENTIFIC CORPORATION $18.64 1
Janssen Biotech, Inc. $14.84 1
EPI Health, LLC $12.89 1

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL T LIN

NPI 1164436820 · CMS profile ID 98087

Allopathic & Osteopathic Physicians / Dermatology

SHERMAN OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164436820?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL T LIN, NPI 1164436820, CMS profile ID 98087. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164436820?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL T LIN, NPI 1164436820, CMS profile ID 98087. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164436820?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL T LIN, NPI 1164436820, CMS profile ID 98087, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1164436820?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $1,634.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $28.0207/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339629 CMS
AbbVie Inc. $8.5107/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339635 CMS
Novartis Pharmaceuticals Corporation $10.6107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030061 CMS
PFIZER INC. $4.9007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833086127 CMS
UCB, Inc. $24.6907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807372963 CMS
Novartis Pharmaceuticals Corporation $16.7607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030057 CMS
LEO Pharma Inc. $18.8607/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842223465 CMS
PFIZER INC. $18.8606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832621217 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.2006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851913079 CMS
UCB, Inc. $18.4906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807352789 CMS
AbbVie Inc. $8.7406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339623 CMS
UCB, Inc. $5.4006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807311109 CMS
Novartis Pharmaceuticals Corporation $9.5406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030053 CMS
AbbVie Inc. $22.6006/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339617 CMS
Amgen Inc. $6.2606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826394251 CMS
Novartis Pharmaceuticals Corporation $7.2705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030049 CMS
UCB, Inc. $21.6705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807356149 CMS
AbbVie Inc. $7.4305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339611 CMS
Lilly USA, LLC $21.9905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818657589 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.3605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851913069 CMS
UCB, Inc. $5.4005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807355833 CMS
Galderma Laboratories, L.P. $13.0405/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855287737 CMS
PFIZER INC. $13.0605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832580527 CMS
UCB, Inc. $47.5305/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807342993 CMS
PFIZER INC. $10.0404/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833287547 CMS
Biofrontera Inc. $24.0404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795993185 CMS
AbbVie Inc. $8.2304/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339605 CMS
Amgen Inc. $20.2104/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826394247 CMS
BOSTON SCIENTIFIC CORPORATION $18.6404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792567379 CMS
AbbVie Inc. $15.9804/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339599 CMS
Allergan, Inc. $14.4604/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792853939 CMS
UCB, Inc. $7.3504/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807342057 CMS
AbbVie Inc. $7.9403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339593 CMS
Janssen Biotech, Inc. $14.8403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787941609 CMS
Novartis Pharmaceuticals Corporation $22.3603/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030041 CMS
AbbVie Inc. $19.8803/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339587 CMS
AbbVie Inc. $23.0902/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339581 CMS
AbbVie Inc. $8.2502/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795339575 CMS
Novartis Pharmaceuticals Corporation $8.2702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030045 CMS
Lilly USA, LLC $21.3501/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818664649 CMS
Amgen Inc. $26.7501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826394245 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.5001/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851913077 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,991.51 87
PY2020 $719.43 33
PY2021 $1,634.19 92
PY2022 $2,304.73 119
PY2023 $4,079.05 145
PY2024 $6,154.73 182
PY2025 $3,861.80 143

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $470,117.55 60
PY2024 Principal investigator $244,946.95 38
PY2023 Principal investigator $10,148.85 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,207.58 12/31/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749484
Principal investigator 1 PFIZER INC. $1,207.58 12/17/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228746273
Principal investigator 1 SANOFI US SERVICES INC. $27,679.50 12/15/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153457
Principal investigator 1 PFIZER INC. $5,137.44 12/03/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228736211
Principal investigator 1 PFIZER INC. $1,508.63 11/26/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228723768
Principal investigator 1 SANOFI US SERVICES INC. $9,418.00 11/24/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226153438
Principal investigator 1 PFIZER INC. $1,190.00 11/19/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739588
Principal investigator 1 PFIZER INC. $384.00 11/19/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228741006
Principal investigator 1 SANOFI US SERVICES INC. $4,719.00 11/17/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153397
Principal investigator 1 SANOFI US SERVICES INC. $23,723.30 11/10/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153380
Principal investigator 1 PFIZER INC. $1,207.58 11/05/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228739160
Principal investigator 1 SANOFI US SERVICES INC. $2,217.51 10/06/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153352
Principal investigator 1 PFIZER INC. $4,500.91 10/04/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228742097
Principal investigator 1 Eli Lilly and Company $5,411.00 10/02/2025 Non-covered Recipient Entity
CURA CLINICAL RESEARCH LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187883810
Principal investigator 1 PFIZER INC. $2,722.28 09/26/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228750313
Principal investigator 1 PFIZER INC. $3,706.28 09/24/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228769331
Principal investigator 1 SANOFI US SERVICES INC. $6,328.87 09/22/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153336
Principal investigator 1 PFIZER INC. $7,123.84 09/19/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228758849
Principal investigator 1 SANOFI US SERVICES INC. $2,820.04 09/15/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153306
Principal investigator 1 SANOFI US SERVICES INC. $29,122.40 09/15/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153310
Principal investigator 1 SANOFI US SERVICES INC. $2,153.64 09/15/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153318
Principal investigator 1 PFIZER INC. $2,804.76 09/12/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753638
Principal investigator 1 PFIZER INC. $1,000.00 09/08/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228712852
Principal investigator 1 PFIZER INC. $3,000.00 09/08/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228712854
Principal investigator 1 SANOFI US SERVICES INC. $2,583.97 08/25/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153327
Principal investigator 1 SANOFI US SERVICES INC. $500.98 08/25/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153334
Principal investigator 1 PFIZER INC. $5,248.71 08/23/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766444
Principal investigator 1 SANOFI US SERVICES INC. $14,906.00 08/18/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226153241
Principal investigator 1 SANOFI US SERVICES INC. $11,856.20 08/18/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153253
Principal investigator 1 UCB SA $7,050.00 08/13/2025 Non-covered Recipient Entity
CURA CLINICAL RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659240
Principal investigator 1 PFIZER INC. $1,721.93 07/29/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764304
Principal investigator 1 PFIZER INC. $10,261.64 07/17/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764321
Principal investigator 1 PFIZER INC. $1,190.00 07/16/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228712850
Principal investigator 1 PFIZER INC. $384.00 07/16/2025 Non-covered Recipient Entity
Cura Clinical Research LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713024
Principal investigator 1 SANOFI US SERVICES INC. $33,308.80 07/14/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153144
Principal investigator 1 SANOFI US SERVICES INC. $3,900.00 07/02/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153188
Principal investigator 1 Amgen Inc. $4,350.00 06/26/2025 Non-covered Recipient Entity
CURA CLINICAL RESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246640563
Principal investigator 1 SANOFI US SERVICES INC. $20,785.10 06/16/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153084
Principal investigator 1 PFIZER INC. $3,797.56 05/30/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228777405
Principal investigator 1 SANOFI US SERVICES INC. $11,770.37 05/19/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153090
Principal investigator 1 SANOFI US SERVICES INC. $28,449.30 05/19/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153097
Principal investigator 1 SANOFI US SERVICES INC. $17,139.80 05/05/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226153011
Principal investigator 1 PFIZER INC. $1,721.93 05/03/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228783880
Principal investigator 1 SANOFI US SERVICES INC. $828.49 04/28/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152980
Principal investigator 1 SANOFI US SERVICES INC. $4,712.40 04/14/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152992
Principal investigator 1 PFIZER INC. $7,539.36 04/09/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228795030
Principal investigator 1 Amgen Inc. $1,550.00 03/25/2025 Non-covered Recipient Entity
CURA CLINICAL RESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246640559
Principal investigator 1 SANOFI US SERVICES INC. $12,069.20 03/24/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152963
Principal investigator 1 SANOFI US SERVICES INC. $21,516.50 03/17/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152910
Principal investigator 1 PFIZER INC. $2,928.42 03/06/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228794635
Principal investigator 1 PFIZER INC. $4,645.91 03/04/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228780039
Principal investigator 1 SANOFI US SERVICES INC. $24,893.10 02/24/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152954
Principal investigator 1 PFIZER INC. $7,350.78 02/11/2025 Non-covered Recipient Entity
Cura Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751240
Principal investigator 1 SANOFI US SERVICES INC. $12,394.90 02/04/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152916
Principal investigator 1 SANOFI US SERVICES INC. $25,260.10 01/21/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152921
Principal investigator 1 SANOFI US SERVICES INC. $1,660.55 01/21/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152936
Principal investigator 1 SANOFI US SERVICES INC. $643.99 01/21/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152942
Principal investigator 1 SANOFI US SERVICES INC. $4,712.40 01/21/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152948
Principal investigator 1 SANOFI US SERVICES INC. $5,368.70 01/13/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152898
Principal investigator 1 SANOFI US SERVICES INC. $822.32 01/13/2025 Non-covered Recipient Entity
Cura Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226152903